Issue link: https://www.e-digitaleditions.com/i/492796
10 April 2015 Tablets & Capsules labeling. The Agency has done neither. It's estimated that about 1 percent of the population has celiac disease, an autoim- mune disorder in which gluten consump- tion may trigger serious health problems. Poll: US consumers prefer generics NEW YORK, NY—More than 80 per- cent of Americans favor generic prescrip- tion medications over brand name prod- ucts, according to a Harris Interactive poll. The same result was reported for a 2009 survey the company conducted. In the latest poll, more than 50 percent of Matures assert they would "always" choose a generic over a brand product, compared with 44 percent of Baby Boomers, 46 percent of Gen Xers, and 33 percent of Millennials. The poll surveyed 2,255 adults. University's clinical trial ethics under fire SAINT PAUL, MN—A report from the state legislative auditor concludes that the University of Minnesota's research prac- tices suffered from "serious ethical issues and numerous conflicts of interest." The report addresses concerns raised when a participant in the university's department of psychiatry committed suicide in 2004 during a clinical trial of antipsychotic medications (quetiapine, risperidone) funded by AstraZeneca. One of the researchers involved in recruiting the patient for the study was also the dece- dent's psychiatrist. A report weeks earlier from the Association for the Accredita- tion of Human Research Protection Pro- grams asserted that the university's insti- tutional ethics committee "lacks expertise to review study protocols." The university has suspended enrollment in all psychi- atric clinical trials until further notice. Continuous manufacturing of pharmaceuticals grows NEW YORK, NY—Several pharmaceu- tical manufacturers, including GSK, John- son & Johnson, Pfizer, Novartis, and Ver- tex, have implemented continuous manufacturing processes. The trend was the subject of a February 8 Wall Street Jour- nal article, and the American Association of Pharmaceutical Scientists' 50th Arden House Conference narrowed the focus to solid oral dosage drug products. The May issue of T&C will include a summary of that conference, held March 16-18 in Bal- timore, MD. Briefly noted…. Biogen Idec, Cambridge, MA, dropped Idec from its name as part of a rebranding initiative. Biogen was founded in 1978 and merged with Idec Pharmaceuticals in 2003. The FDA approved Merck's Dutrebis (lamivudine 150 milligram/raltegravir 300 milligram) tablets to treat HIV infection. Thomson Reuters predicts 11 new-to- market "blockbusters" in 2015, compared to three in 2014, in its "Drugs to Watch" report. Among them: sacubitril/valsartan for cardiovascular disease, brexpiprazole for psychiatric disorders, and Viekira Pak (veruprevir, ritonavir, ombitsvir, and dasabuvir) for hepatitis C. BROOKFIELD Now on T&C ' s website: • Industry Events • Tools & Resources • Online Buyer's Guide Follow us on Twitter @TabletsCapsules Can't find what you need? E-mail us at: tc@cscpub.com W W W . T A B L E T S C A P S U L E S . C O M